high mobility group 20BGenealiases: BRAF25 · BRAF35 · HMGX2 · HMGXB2 · PP7706 · SMARCE1r
Q-omics provides the consensus-scored HMG20B profile across patient tissues and cancer cell-line models. HMG20B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, HMG20B is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, HMG20B RNA expression shows 20,100 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where HMG20B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMG20B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMG20B survival associations across molecular data types. HMG20B RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMG20B RNA expression–survival associations across cancer types. High HMG20B expression shows unfavorable associations in ACC, UCS and KICH, but favorable associations in UCEC, BLCA and UVM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for HMG20B RNA expression.
This table summarizes HMG20B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in LIHC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for HMG20B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMG20B shows higher tumor expression in HNSC, LIHC, COAD, KIRC, LUSC and BRCA. The HNSC box plot shows higher HMG20B RNA expression in tumor versus normal tissue (log2 FC = +1.326, t-test p < 0.001).
This table shows molecular features associated with HMG20B in patient tissues and cancer cell lines. In patient samples, HMG20B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, HMG20B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SOFT_TISSUE.
